What is Cytokinetics Inc?

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining.

Who owns Cytokinetics?

Cytokinetics

Where is cytokinetics located?

South San Francisco
Overview Suggest Edit

When was cytokinetics founded?

1997
Cytokinetics/Founded

Why did Cytk stock drop?

After losing $91.1 million during the first nine months of 2019, Cytokinetics finished September with just $166 million in cash and short-term investments. Without any products to sell, the company’s going to need more cash to support the continuing development of its clinical-stage pipeline.

How does Omecamtiv Mecarbil work?

Omecamtiv mecarbil activates cardiac myosin and augments the speed of ATP hydrolysis, thus accelerating the production of a strong actin-myosin complex, which leads to increased force production. ADP, adenosine diphosphate; ATP, adenosine triphosphate; Pi, inorganic phosphate.

Is Cytokinetics stock a buy?

Cytokinetics has received a consensus rating of Buy. The company’s average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.

Is omecamtiv mecarbil FDA approved?

Omecamtiv mecarbil (not FDA-approved) is in a new class of drugs (“myotropes”) that enhance cardiac myosin’s binding to actin. In a previous study of patients with HFrEF, omecamtiv improved cardiac performance, assessed with echocardiography and brain-type natriuretic peptide (BNP) levels.

What is a myosin activator?

The first-in-class cardiac myosin activator, omecamtiv mecarbil, augments the speed of ATP hydrolysis, thus accelerating the production of a strong actin-myosin complex, which leads to increased force production. It produces dose-dependent increases in SET, SV, ejection fraction and fractional shortening.

Is cytokinetics a good buy?

Will CYTK stock go up?

Will Cytokinetics stock price grow / rise / go up? Yes. The CYTK stock price can go up from 32.410 USD to 38.109 USD in one year.

What kind of company is Cytokinetics, Inc.?

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining.

What do you need to know about Cytokinetics?

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining.

What does Cytokinetics do in the Bay Area?

Cytokinetics is committed to our mission of developing potential medicines that may improve the healthspan of people living with cardiovascular and neuromuscular diseases of impaired muscle function. Cytokinetics is proud to be recognized as one of the 2021 Best Places to Work in the Bay Area by the San Francisco Business Times.

When was Cytokinetics muscle biology therapies founded?

Cytokinetics was founded in 1998 by pioneers in the field of muscle biology. Over the years, our company has developed an unparalleled expertise, keeping it at the forefront of drug discovery and development for diseases impacting muscle performance.